Docetaxel (Taxotere) and Imatinib Mesylate (Gleevec) in Hormone Refractory Prostate Cancer
Status:
Terminated
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
This trial is designed to determine the proper doses of Docetaxel and Imatinib mesylate to be
used to treat hormone refractory prostate cancer and to evaluate the safety and efficacy of
the treatment.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
New York University School of Medicine NYU Langone Health